Eluxadoline
| Clinical data | |
|---|---|
| Pronunciation | Viberzi (/vaɪˈbɜːrzi/ vy-BUR-zee | 
| Trade names | Viberzi, Truberzi | 
| Other names | JNJ-27018966 | 
| Routes of administration | By mouth | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Protein binding | 81% | 
| Elimination half-life | 3.7–6 hours | 
| Excretion | 82.2% (feces), <1% (urine) | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C32H35N5O5 | 
| Molar mass | 569.662 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Eluxadoline, sold under the brand names Viberzi and Truberzi, is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.